TrialThe Lancet. Neurology2010

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Juha O Rinne et al.PubMed ↗Publisher ↗

No numbers read from the abstract.